Discordant use of short-acting β₂ agonists in children and adults with severe, uncontrolled asthma from the U-BIOPRED cohort

TY - JOUR

T1 - Discordant use of short-acting β2 agonists in children and adults with severe, uncontrolled asthma from the U-BIOPRED cohort

AU - The U-Biopred Study Group

AU - Gorlanova, Olga

AU - Tischhauser, Eveline

AU - Adcock, Ian M.

AU - Chung, Kian Fan

AU - Fleming, Louise

AU - Meier, Delphine

AU - Sterk, Peter J.

AU - Roberts, Graham

AU - Roberts, Amanda

AU - Singer, Florian

AU - Sousa, Ana R.

AU - Uddin, Mohib

AU - Frey, Urs

N1 - Funding Information: U‐BIOPRED is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115010, resources of which are composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007‐2013) and EFPIA companies' in‐kind contribution ( https://www.imi.europa.eu ). The authors would like to acknowledge help from the IMI‐funded eTRIKS project (EU Grant Code no. 115446). This study is registered on https://ClinicalTrials.gov (identifier: NCT01982162). Funding Information: U-BIOPRED is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115010, resources of which are composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution (https://www.imi.europa.eu). The authors would like to acknowledge help from the IMI-funded eTRIKS project (EU Grant Code no. 115446). This study is registered on https://ClinicalTrials.gov (identifier: NCT01982162). Funding Information: Mohib Uddin is an employee of AstraZeneca and holds shares in the company. Florian Singer reports personal fees from Vertex, personal fees from Novartis, grants from Swiss Society of Cystic Fibrosis (CFCH), grants from LUNGENLIGA BERN, outside the submitted work. Peter J. Sterk reports grants from public‐private funding to his institute by the Innovative Medicines Initiative covered by the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), during the conduct of the study. Ian M. received grants from EU‐IMI, during the conduct of the study. The other authors declare that there are no conflict of interests.

PY - 2021/2

Y1 - 2021/2

KW - misperception

KW - severe asthma

KW - short-acting beta agonist

UR - http://www.scopus.com/inward/record.url?scp=85096666786&partnerID=8YFLogxK

U2 - https://doi.org/10.1002/ppul.25171

DO - https://doi.org/10.1002/ppul.25171

M3 - Article

C2 - 33231935

SN - 8755-6863

VL - 56

SP - 338

EP - 340

JO - Pediatric pulmonology

JF - Pediatric pulmonology

IS - 2

ER -